Mirum Pharmaceuticals (MIRM) Enterprise Value (2018 - 2026)

Mirum Pharmaceuticals has reported Enterprise Value for 9 years, with the latest figure at -$386.3 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 39.11% year-over-year to -$386.3 million; the trailing twelve-month figure through Mar 2026 stood at -$386.3 million (down 39.11% YoY), and the FY2025 full-year result was -$383.3 million, down 36.54% from the prior year.
• Enterprise Value for Q1 2026 stood at -$386.3 million, down from -$383.3 million in the prior quarter.
• The five-year high for Enterprise Value was -$125.0 million in Q2 2022, with the low at -$434.9 million in Q3 2022.
• Average Enterprise Value over 5 years is -$298.4 million, with a median of -$302.8 million recorded in 2024.
• Peak annual rise in Enterprise Value reached 60.4% in 2023, while the deepest fall reached 164.06% in 2023.
• Tracing MIRM's Enterprise Value over 5 years: stood at -$251.7 million in 2022, then decreased by 13.75% to -$286.3 million in 2023, then rose by 1.95% to -$280.7 million in 2024, then tumbled by 36.54% to -$383.3 million in 2025, then dropped by 0.76% to -$386.3 million in 2026.
• The last three Enterprise Value figures came in at -$386.3 million (Q1 2026), -$383.3 million (Q4 2025), and -$375.5 million (Q3 2025), per Business Quant data.

Peer Comparison